Wedbush Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices slip as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
H.C. Wainwright Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition
December 3, 2019 7:15 AM ESTH.C. Wainwright analyst Debjit Chattopadhyay downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreMizuho Securities Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition
December 3, 2019 6:53 AM ESTMizuho Securities analyst Difei Yang downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral with a price target of $60.00.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreRaymond James Downgrades Audentes Therapeutics (BOLD) to Market Perform Following Acquisition
December 3, 2019 6:26 AM ESTRaymond James analyst Steven Seedhouse downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreOptions expected to have increasing volume: BOLD UNH ATHM CRM WDAY
December 3, 2019 5:27 AM ESTOptions expected to have increasing volume: BOLD UNH ATHM CRM WDAY
... MoreBMO Capital Downgrades Audentes Therapeutics (BOLD) to Market Perform Following Acquisition
December 3, 2019 5:07 AM ESTBMO Capital analyst Matthew Luchinitthew Lichini downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Market Perform with a price target of $60.00 (from $47.00).
For an analyst ratings summary and ratings history on Audentes Therapeutics click... More
Piper Jaffray Downgrades Audentes Therapeutics (BOLD) to Neutral
December 3, 2019 4:32 AM ESTPiper Jaffray analyst Christopher Raymond downgraded Audentes Therapeutics (NASDAQ: BOLD) from Overweight to Neutral with a price target of $60.00 (from $55.00).
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreBaird Upgrades Audentes Therapeutics (BOLD) to Neutral
December 3, 2019 4:32 AM ESTBaird analyst Madhu Kumar upgraded Audentes Therapeutics (NASDAQ: BOLD) from Underperform to Neutral with a price target of $60.00 (from $10.00).
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreCiti Upgrades Audentes Therapeutics (BOLD) to Neutral
December 3, 2019 4:31 AM ESTCiti analyst Mohit Bansal upgraded Audentes Therapeutics (NASDAQ: BOLD) from Sell to Neutral with a price target of $60.00 (from $30.00).
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreGuggenheim Downgrades Audentes Therapeutics (BOLD) to Neutral
December 3, 2019 4:31 AM ESTGuggenheim analyst Whitney Ijem downgraded Audentes Therapeutics (NASDAQ: BOLD) from Buy to Neutral.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $28.61 yesterday.
... MoreJapan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet
December 2, 2019 6:29 PM ESTTOKYO (Reuters) - Japan's Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc (NASDAQ: BOLD) for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.
Gene therapies are one of the hottest areas of drug research and Astellas, Japan's second-largest drugmaker by sales, is offering $60 per share for San Francisco-based Audentes, a 110% premium to its closing price on Monday.
Citi analyst Hidemaru Yamaguchi said that while the deal looked expensive, it was a positive move for Astellas as Audentes had "cutting-edge... More
After-Hours Movers 12/02: (BOLD) (VRAY) (ILPT) Higher; (CBL) (AGTC) (KOD) Lower (more...)
December 2, 2019 6:08 PM ESTToday's After-Hours Movers
Audentes Therapeutics, Inc. (NASDAQ: BOLD) 109% HIGHER; Astellas Pharma Inc. and Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
CBL Properties (NYSE: CBL) 33% LOWER; announced that it is suspending all future dividends on its common stock, 7.375% Series D Cumulative Redeemable Preferred... More
Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share
December 2, 2019 6:02 PM ESTAstellas Pharma Inc. and Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
Recent scientific and technological advances in genetic medicine have advanced the potential to deliver unprecedented and sustained value to patients, and even to curing diseases with a single intervention, said Kenji Yasukawa, President and CEO, Astellas. Audentes has developed a robust pipeline of promising product candidates which are complementary to our existing... More
Audentes Therapeutics (BOLD) halted, news pending
December 2, 2019 6:00 PM ESTAudentes Therapeutics (NASDAQ: BOLD) halted, news pending
... More
